Synonyms: example 8 [US20210047309] | GBT-021601 | GBT-601 | GBT021601
Compound class:
Synthetic organic
Comment: Osivelotor (GBT021601; Global Blood Therapeutics) is a clinical lead for the treatment of sickle cell disease. It stablilises sickle haemoglobin (HbS) in its oxygenated state which inhibits its polymerisation (the underlying cause of erythrocyte sickling) [3]. Based on preclinical studies osivelotor is proposed as an oral drug to reduce vaso-occlusive crises in people with sickle cell disease [1].
|
|
References |
1. Dufu K, Alt C, Strutt S, Partridge J, Tang T, Siu V, Liao-Zou H, Rademacher P, Williams AT, Muller CR et al.. (2023)
GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. Br J Haematol, 202 (1): 173-183. [PMID:36960712] |
2. FDA.
(S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin- 3-yl)methoxy)benzaldehyde. Accessed on 07/08/2023. Modified on 07/08/2023. fda.gov, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=877122 |
3. Li Z. (2023)
Modulators of hemoglobin. Patent number: US20210047309A1. Assignee: Global Blood Therapeutics Inc. Priority date: 04/05/2020. Publication date: 10/01/2023. |